Calibrated Bayesian inference for overall and subgroup-specific causal effects in stepped-wedge cluster-randomized trials
阶梯楔形整群随机试验中总体与亚组因果效应的校准贝叶斯推断AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要以加权平均处理效应、亚组因果估计量与模型稳健标准化为核心,属于因果推断方向;其余细分方向在摘要中缺乏直接文本依据。
阶梯楔形整群随机试验中总体与亚组因果效应的校准贝叶斯推断AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
Stepped-wedge cluster-randomized trials (SW-CRTs) randomly assign clusters to sequences that determine when each cluster switches from control to intervention. Conventional Bayesian analyses of SW-CRTs report treatment effect coefficients from a working outcome model, but under model misspecification or informative cluster-period sizes, such coefficients can lack a clear causal interpretation. In this work, we develop Bayesian methods targeting weighted average treatment effect estimands in SW-CRTs, including novel subgroup-specific causal estimands defined by baseline characteristics. We compare model-based g-computation with model-robust standardization, implementing both with linear mixed models and mixed-effects Bayesian additive regression trees as working outcome models, and propose a calibrated variance estimator that augments posterior parameter uncertainty with cluster-level resampling to better capture sampling variability. In simulations with outcome model misspecification and informative cluster-period sizes, model-robust standardization with calibrated inference exhibits negligible bias and near-nominal frequentist coverage for overall and subgroup-specific causal effects, whereas g-computation and uncalibrated intervals become insufficient. We illustrate the proposed methods with a reanalysis of the Trauma Survivors Outcomes and Support trial.